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Antimicrobial susceptibilities were determined for 1,586 isolates of Stenotrophomonas maltophilia from
globally diverse medical centers using the Clinical Laboratory Standards Institute broth microdilution
method. The combination trimethoprim-sulfamethoxazole (96.0% of isolates susceptible at <2 g/ml tri-
methoprim and 38 g/ml sulfamethoxazole) and tigecycline (95.5% of isolates sussceptible at <2 g/ml) were
the only antimicrobials tested with >94% susceptibility in all regions. Susceptibility rates for other commonly
used were lower than expected and varied geographically. This in vitro data supports tigecycline as a potential
candidate for clinical investigations into S. maltophilia infections.
Stenotrophomonas maltophilia is a Gram-negative bacillus,
inherently multidrug resistant (MDR) and frequently recov-
ered from environmental sources. It has been associated with
severe nosocomially acquired bacteremia and pneumonia, usu-
ally among immunocompromised patients, as well as meningi-
tis, endocarditis, and urinary tract, skin/soft tissue, and ocular
infections. S. maltophilia infections are associated with high
morbidity and mortality, with estimated crude mortality rates
ranging from 20 to 70% and with the risk of mortality highest
among patients receiving inappropriate initial antimicrobial
therapy (5). Treatment of S. maltophilia infections represents a
significant challenge because of the organism’s high levels of
intrinsic resistance to many antimicrobial agents, difficulties in
susceptibility testing, the development of resistance during
therapy, and the paucity of clinical trials to determine optimal
therapy (8, 12).
The combination trimethoprim-sulfamethoxazole (TMP/
SMX) is the recognized antimicrobial of choice for the treatment
of infections caused by S. maltophilia with ceftazidime, ticarcillin-
clavulanate, minocycline, tigecycline, fluoroquinolones, and the
polymyxins being described as alternative therapies. It is impor-
tant to note that all recommended therapy options have been
based on in vitro studies and anecdotal experience rather than
appropriately structured clinical trials (11). Resistance to TMP/
SMX has been described and varies geographically, being shown
by as many as 10% of isolates in Europe (7). In addition, allergic
reactions to the combination TMP/SMX are common and can be
severe, which further compromises its application (1). Clearly,
therapeutic alternatives are needed to treat infections caused by
S. maltophilia.
Tigecycline is a 9-t-butylglycylamido derivative of minocy-
cline and is the first glycylcycline licensed for clinical use.
Tigecycline binds to the 30S ribosomal subunit, resulting in
inhibition of protein synthesis (13). It exhibits a wide range of
activity against Gram-positive and -negative organisms, includ-
ing MDR strains. Tigecycline is approved by the United States
Food and Drug Administration (USFDA) for the treatment of
complicated skin and skin structure infections (cSSSI), intra-
abdominal infections, and, more recently, community-acquired
bacterial pneumonia. Tigecycline has demonstrated good in
vitro activity against S. maltophilia in several studies (6, 9, 14).
The aim of this study was to assess antimicrobial resistance in
S. maltophilia against commonly used agents by using the larg-
est and most geographically diverse collection of contemporary
isolates available, with the rationale being the paucity of such
information in the face of a clear need for clinical and research
options.
From January 2003 to December 2008, a total of 1,586
unique clinical S. maltophilia strains were recovered and iden-
tified from 119 medical centers located across Asia and the
Pacific (Asian-Pacific), Europe, Latin America, and North
America. Bacterial identification was confirmed by the central
monitoring site (JMI Laboratories, North Liberty, IA) using
standard algorithms (microscopy, culture characteristics, and
oxidase reaction) followed by an automated system (Vitek 2;
bioMerieux, Hazelwood, MO). MIC values were determined
for all isolates based on the Clinical Laboratory Standards
Institute (CLSI) broth microdilution method using commer-
cially prepared and validated panels (TREK Diagnostic Sys-
tems, Cleveland, OH) in fresh cation-adjusted Mueller-Hinton
broth (2). Tigecycline breakpoints established by the USFDA
for Enterobacteriaceae (2 g/ml for susceptibility and 8
g/ml for resistance) as well as the polymyxin B breakpoints
established by the CLSI for P. aeruginosa (2 g/ml for sus-
ceptibility and 8 g/ml for resistance), were applied for com-
parison only (Tygacil; Wyeth Pharmaceuticals, Philadelphia,
PA). CLSI quality control ranges and interpretive criteria were
used for comparator compounds (3).
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Clinical sites of infection for S. maltophilia were primarily
bloodstream (51%) and respiratory tract (37%). Tigecycline
activities were similar across the four geographic regions (94.5
to 96.5% of isolates inhibited at 2 g/ml) and were most
similar to those of TMP/SMX (90.8 to 98.9% of isolates sus-
ceptible) (Tables 1 and 2). When tested against S. maltophilia
isolates from North America and Europe, TMP/SMX was the
most active compound (MIC50, 0.5 g/ml and MIC90, 1 g/
ml; 97.6 to 98.9% of isolates susceptible), followed by tigecy-
cline (MIC50, 1 g/ml, and MIC90, 2 g/ml; 94.5 to 95.3% o
isolates susceptible) and levofloxacin (MIC50, 1 g/ml, and
MIC90, 4 g/ml; 82.5 to 83.7% of isolates susceptible) (Table
2). Tigecycline was the most active compound tested against S.
maltophilia isolates from the Asian-Pacific and Latin American
regions (MIC50, 0.5 g/ml, and MIC90, 2 g/ml; 96.1 to 96.5%
of isolates susceptible), followed by TMP/SMX (MIC50, 0.5
g/ml, and MIC90, 1 g/ml; 90.8 to 95.5% of isolates suscep-
tible) (Table 2). Levofloxacin exhibited good in vitro activity
against S. maltophilia isolates from Latin America (91.3% sus-
ceptible), but its activity was more restricted when tested
against isolates from other geographic regions (78.0 to 83.7%
of isolates susceptible) (Table 2). In general, ceftazidime (32.6
to 51.0% of isolates susceptible), ticarcillin-clavulanate (27.0 to
46.1% of isolates susceptible), and polymyxin B (33.4 to 76.4%
of isolates susceptible) showed the most limited in vitro activ-
ities against S. maltophilia.
Tigecycline exhibited similar potencies across all geographic
regions, and its antimicrobial activity was similar to that of
TMP/SMX. Overall, tigecycline showed a greater potency
against S. maltophilia than levofloxacin, ceftazidime, and ticar-
cillin-clavulanate. Tigecycline and TMP/SMX were the only
antimicrobial agents tested with susceptibility rates of90% in
all regions and overall. Prevalence of resistance to alternative
therapies varied geographically and was higher than expected
or previously reported for these antimicrobials in some geo-
graphic regions. There is some evidence to suggest that resis-
tance to alternative drugs could be increasing. Ticarcillin-
clavulanate susceptibility was reported as 59.1% in Brazil in 70
clinical isolates collected between 2000 and 2002 (10), com-
pared to our data which show susceptibility at 39.1% for ticar-
cillin-clavulanate in several Latin American nations, including
Brazil. This data highlights the need for continued antimicro-
bial resistance surveillance at the local level, especially for
these alternative agents.
Few treatment options are available to treat S. maltophilia
infections, and this study demonstrates that antimicrobial re-
sistance to alternate antimicrobial agents is higher than pro-
jected and geographically varied. Infections caused by S. mal-
TABLE 1. Regional MIC distributions for tigecycline tested against 1,586 S. maltophilia strains, stratified by geographic region
Region (no. of
strains tested)
Cumulative % inhibited at tigecycline MIC (g/ml) of:
0.12 0.25 0.5 1 2a 4 4
North America (491) 2.2 16.5 49.7 79.8 94.5 98.4 100.0
Europe (447) 1.8 13.7 48.1 83.5 95.3 99.3 100.0
Asian-Pacific (359) 1.4 12.5 57.9 87.5 96.1 99.2 100.0
Latin America (289) 1.7 15.2 52.3 87.5 96.5 100.0
All regions (1,586) 1.8 14.6 51.6 84.0 95.5 99.1 100.0
a Susceptibility breakpoint established by the CLSI for Enterobacteriaceae (3).
TABLE 2. Antimicrobial activity of tigecycline and comparator
agents tested against S. maltophilia isolates from four
geographic regions
Region (no. of strains tested)
and antimicrobial agent
MIC
(g/ml)a % of isolates
50% 90% Susceptible Resistant
North America (491)
Tigecycline 1 2 94.5b 1.6b
Ceftazidime 8 16 51.0 34.9
Levofloxacin 1 4 82.5 8.4
Polymyxin B 1 4 73.2c 17.4c
Ticarcillin-clavulanate 32 128 46.1 17.6
TMP/SMXd 0.5 1 97.6 2.4
Europe (447)
Tigecycline 1 2 95.3b 0.7b
Ceftazidime 16 16 45.2 43.6
Levofloxacin 1 4 83.7 8.5
Polymyxin B 1 4 72.6c 16.2c
Ticarcillin-clavulanate 32 128 42.7 16.2
TMP/SMX 0.5 1 98.9 1.1
Asian-Pacific (359)
Tigecycline 0.5 2 96.1b 0.8b
Ceftazidime 16 16 32.6 53.5
Levofloxacin 1 4 78.0 11.7
Polymyxin B 4 4 33.4c 57.7c
Ticarcillin-clavulanate 64 128 27.0 35.1
TMP/SMX 0.5 1 90.8 9.2
Latin America (289)
Tigecycline 0.5 2 96.5b 0.0b
Ceftazidime 16 16 48.8 38.4
Levofloxacin 1 2 91.3 3.8
Polymyxin B 1 4 76.4c 14.9c
Ticarcillin-clavulanate 32 128 36.7 22.5
TMP/SMX 0.5 1 95.5 4.5
All regions (1,586)
Tigecycline 0.5 2 95.5b 0.9b
Ceftazidime 16 16 4.8 42.2
Levofloxacin 1 4 83.4 83
Polymyxin B 1 4 64.6c 25.7c
Ticarcillin-clavulanate 32 128 39.1 24.2
TMP/SMX 0.5 1 96.0 4.0
a 50% and 90%, MIC50 and MIC90, respectively.
b Tigecycline breakpoints established by the USFDA (Tygacil; Wyeth Phar-
maceuticals, Philadelphia, PA) for Enterobacteriaceae (2 g/ml for susceptibil-
ity and 8 g/ml for resistance) were applied for comparison only.
c Polymyxin B breakpoints established by the CLSI (3) (Tygacil; Wyeth Phar-
maceuticals, Philadelphia, PA) for P. aeruginosa (2 g/ml for susceptibility and
8 g/ml for resistance) were applied for comparison only.
d TMP/SMX, trimethoprim-sulfamethoxazole.
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tophilia are life threatening and have a high mortality, and the
lack of evidence-based therapeutic options often forces clini-
cians to make difficult decisions regarding antimicrobial ther-
apy. The role of tigecycline in the treatment of S. maltophilia
infections warrants further investigation due to its high in vitro
activity and potency. Synergies between tigecycline and TMP/
SMX and also amikacin have been reported, and hence com-
bination therapy would be a potential approach for clinical
investigations and experimental therapy trials (4).
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